EXO BIOLOGICS
LIVE

Serial Number

98320218

Owner

EXO Biologics SA

Attorney

Neil B Friedman

Filing Date

Dec 18, 2023

Add to watchlist:

No watchlists yet
View on USPTO

EXO BIOLOGICS Trademark

Serial Number: 98320218

EXO BIOLOGICS is a trademark filed by EXO Biologics SA on December 18, 2023. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently pending registration.

Owner Contact Info

EXO Biologics SA

Boulevard de Patience et Beaujonc 3/2
Liège 4000 , BE

Entity Type: 99

Trademark Details

Filing Date

December 18, 2023

Registration Date

Not Registered

Goods & Services

Research and development for others of pharmaceutical molecules or biological markers for diagnostic purposes and medicines for treating diseases; chemical analyses; chemical research; chemical analysis services, namely, analysis of RNA genes, tissues and blood samples; scientific research in the nature of biotechnological project studies for identifying people suffering from diseases and to measure the seriousness, prognoses, progression and conversion of the disease and to determine how patients respond to treatments, especially personalized treatments; research and development of new products for others; biological research; biotechnological research; technical research in the field of biotechnology; biotechnological analysis services; laboratory analysis services, namely, quantification of nucleic acid content intended for medical and scientific research; consultancy in the field of biotechnology; Consulting services in the field of pharmaceutical research, namely, selection of individuals for clinical trials; none of the aforesaid services being for use in relation to ultrasound-based medical, diagnostic or therapeutic imaging apparatus or devices used for medical, diagnostic or therapeutic imaging and related software

Medical services; veterinary services; medical assistance; hospital services; preparation of prescriptions by pharmacists for geriatric or neurological diagnoses and treatment; health care; telemedicine services; none of the aforesaid services being for use in relation to ultrasound-based medical, diagnostic or therapeutic imaging apparatus or devices used for medical, diagnostic or therapeutic imaging and related software

Pharmaceutical products for the treatment of cancer, lung, eye, skin, gastrointestinal, inflammatory, auto-immune or infectious disorders and diseases; reagents for diagnostic purposes and diagnostic media intended for medical purposes, namely, reagents and media intended for tests, namely, tests based on blood biomarkers for identifying patients affected by diseases or those at risk of developing a disease and for identifying patients responding to specific personalized treatments; biological acidic products and preparations for pharmaceutical purposes, namely, diagnostic preparations for medical use; capsules sold empty for medicines and medical diagnostic reagents tests; chemico-pharmaceutical preparations for the prevention or treatment of cancer, lung, eye, skin, gastrointestinal, inflammatory, auto-immune or infectious disorders and diseases; biopharmaceutical products for the prevention or treatment of cancer, lung, eye, skin, gastrointestinal, inflammatory, auto-immune, or infectious disorders and diseases; chemical preparations for medical, pharmaceutical or veterinary purposes, namely, chemical preparations for diagnosing lung, eye, skin, gastrointestinal, inflammatory, auto-immune, or infectious disorders and diseases, neurodegenerative diseases and cancers; medical diagnostic products and clinical diagnostic products, namely, probes and kits for medical and clinical diagnosis including nucleic acid libraries, nucleic acids on DNA chips; DNA libraries and RNA libraries for medical diagnostic purposes and companion diagnostic purposes; nucleic acid sequences intended for use in chips for medical purposes and medical diagnostic purposes, namely, for decoding genes affected by diseases or revealing the transcriptomic signature of patients affected by diseases; enzymes or enzyme preparations for medical or veterinary purposes, namely, enzyme stabilizers and enzymatic substrates for use as ingredients in medicines for the treatment of diseases; reagents for medical use contained in diagnostic test kits for taking blood samples required for the preservation of the biological material under analysis in order to carry out the test under the appropriate conditions; none of the aforesaid goods being for use in relation to ultrasound-based medical, diagnostic or therapeutic imaging apparatus or devices used for medical, diagnostic or therapeutic imaging and related software

Filing History

REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED
May 8, 2026 RCSC
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Apr 26, 2026 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Oct 10, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Oct 10, 2025 GNSL
SUSPENSION LETTER WRITTEN
Oct 10, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Sep 30, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 30, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Sep 30, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 19, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jul 19, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jul 19, 2024 CNRT
ASSIGNED TO EXAMINER
Jul 17, 2024 DOCK
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Jul 2, 2024 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jul 2, 2024 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 30, 2024 NWOS
NEW APPLICATION ENTERED
Dec 23, 2023 NWAP